Alembic Pharmaceuticals
Alembic Pharmaceuticals Ltd., a prominent player in the global pharmaceutical industry, is headquartered in Vadodara, India. Founded in 1907, the company has established itself as a leader in the development and manufacturing of generic and branded pharmaceuticals, with a strong presence in both domestic and international markets. Specialising in a diverse range of therapeutic areas, Alembic Pharmaceuticals offers a unique portfolio that includes injectables, oral solids, and specialty products. The company is renowned for its commitment to quality and innovation, which has led to significant milestones, including successful product launches and regulatory approvals across various regions. With a robust market position, Alembic Pharmaceuticals has garnered recognition for its research and development capabilities, making it a trusted partner in the healthcare sector. Its dedication to advancing healthcare solutions continues to drive its growth and success in the competitive pharmaceutical landscape.
DitchCarbon Score
How does Alembic Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alembic Pharmaceuticals's score of 0 is lower than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Alembic Pharmaceuticals's reported carbon emissions
In 2023, Alembic Pharmaceuticals reported total carbon emissions of approximately 65,892,530 kg CO2e for Scope 1 and about 83,482,350 kg CO2e for Scope 2. This indicates a significant commitment to tracking and managing their carbon footprint. In 2024, emissions slightly increased, with Scope 1 emissions at approximately 70,977,700 kg CO2e and Scope 2 emissions at about 67,544,140 kg CO2e. Despite these figures, there are currently no publicly disclosed reduction targets or climate pledges from Alembic Pharmaceuticals. The company has not specified any initiatives under the Science Based Targets initiative (SBTi) or other formal reduction commitments. This lack of defined targets may reflect a broader industry context where many pharmaceutical companies are still developing comprehensive climate strategies. Alembic Pharmaceuticals' emissions intensity metrics indicate a focus on improving efficiency, with emissions intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP) reported at approximately 2.95e-08 in 2023 and 2.74e-08 in 2024. Additionally, the emissions intensity in terms of physical output was about 25,850 kg CO2e per tonne in 2023 and 26,950 kg CO2e per tonne in 2024, while emissions per employee were approximately 10,240 kg CO2e in 2023 and 9,320 kg CO2e in 2024. Overall, while Alembic Pharmaceuticals is actively monitoring its emissions, the absence of specific reduction targets highlights an area for potential growth in their climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 65,892,530 | 00,000,000 |
| Scope 2 | 83,482,350 | 00,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Alembic Pharmaceuticals is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
